KR920017652A - 신경보호활성을 갖는 α-디하이드로 에르고크립틴 약제학적 제제 - Google Patents
신경보호활성을 갖는 α-디하이드로 에르고크립틴 약제학적 제제 Download PDFInfo
- Publication number
- KR920017652A KR920017652A KR1019920004973A KR920004973A KR920017652A KR 920017652 A KR920017652 A KR 920017652A KR 1019920004973 A KR1019920004973 A KR 1019920004973A KR 920004973 A KR920004973 A KR 920004973A KR 920017652 A KR920017652 A KR 920017652A
- Authority
- KR
- South Korea
- Prior art keywords
- dihydroergocriptine
- medicament
- administration
- pharmaceutical formulation
- ergocriptine
- Prior art date
Links
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 title claims 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000004958 brain cell Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 신경세포의 생존상태에 대한 α-DHEK의 활성을 보여주는 그라프이고,
제2도는 지연성 Ca++유입에 대한 α-DHEK의 활성을 보여주는 그라프이고,
제3도는 도파민 갑소로 나타나는 MPTP의 신경독성 작용에 대한 α-DHEK의 활성을 보여주는 그라프.
Claims (6)
- α-디하이드로에르고크립틴 또는 생리학적으로 허용되는 그의 염을 사용하는 것을 특징으로 하는, 환자의 신경보호 및 내인성·외인성 독성물질에 의해 야기되는 뇌세포 괴사의 예방용 약제의 제조방법.
- 제1항에 있어서, 상기 α-디하이드로에르고크립틴의 염이 메탄설폰산염인 것을 특징으로 하는 제조방법.
- 제1항에 있어서, 상기 α-디하이드로에르고크립틴이 0.5내지 100mg/일의 양으로 투여하기에 적절한 단위 용량으로 약제중에 함유되는 것을 특징으로 하는 제조방법.
- 제2항에 있어서, 상기 α-디하이드로에르고크립틴이 0.5내지 100mg/일의 양으로 투여하기에 적절한 단위 용량으로 약제중에 함유되는 것을 특징으로 하는 제조방법.
- 제1항 내지 제4항의 어느 한 항에 있어서, 상기 약제가 경구, 설하, 비경구, 경피, 및 비강내 투여에 적합한 약제학적 제제의 형태인 것을 특징으로 하는 제조방법.
- 제5항에 있어서, 상기 약제학적 제제가 캅셀, 정제, 환제, 점적제, 경구용 지속적 방출제제, 비강내 투여용 제제, 비경우 정맥내 및 근육내투여용 앰플을 포함하는 것을 특징으로 하는 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI91A000843 | 1991-03-28 | ||
| ITMI910843A IT1245369B (it) | 1991-03-28 | 1991-03-28 | Medicamento contenente alfa-diidroergocriptina ad azione neuroprotettrice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR920017652A true KR920017652A (ko) | 1992-10-21 |
| KR100196445B1 KR100196445B1 (ko) | 1999-06-15 |
Family
ID=11359300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920004973A KR100196445B1 (ko) | 1991-03-28 | 1992-03-26 | 신경보호활성을 갖는 알파-디하이드로에르고크립틴 약제학적 제제 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0505608B1 (ko) |
| JP (1) | JPH04312590A (ko) |
| KR (1) | KR100196445B1 (ko) |
| AT (1) | ATE183093T1 (ko) |
| CA (1) | CA2064112C (ko) |
| DE (2) | DE69131521T2 (ko) |
| DK (1) | DK0505608T3 (ko) |
| ES (1) | ES2052467T1 (ko) |
| GR (1) | GR920300126T1 (ko) |
| IT (1) | IT1245369B (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20041855A1 (it) * | 2004-09-29 | 2004-12-29 | Polichem Sa | Composizioni farmaceutiche di alfa-diidroergocriptina per uso transdermico e-o transmucoso. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1200603B (it) * | 1985-04-04 | 1989-01-27 | Poli Ind Chimica Spa | Composizione farmaceutiche ad attivita dopaminergica |
-
1991
- 1991-03-28 IT ITMI910843A patent/IT1245369B/it active IP Right Grant
- 1991-09-25 ES ES91116311T patent/ES2052467T1/es active Pending
- 1991-09-25 AT AT91116311T patent/ATE183093T1/de active
- 1991-09-25 EP EP91116311A patent/EP0505608B1/en not_active Expired - Lifetime
- 1991-09-25 DE DE69131521T patent/DE69131521T2/de not_active Expired - Lifetime
- 1991-09-25 DK DK91116311T patent/DK0505608T3/da active
- 1991-09-25 DE DE199191116311T patent/DE505608T1/de active Pending
- 1991-09-27 JP JP3249414A patent/JPH04312590A/ja active Pending
-
1992
- 1992-03-26 CA CA002064112A patent/CA2064112C/en not_active Expired - Lifetime
- 1992-03-26 KR KR1019920004973A patent/KR100196445B1/ko not_active IP Right Cessation
-
1993
- 1993-03-16 GR GR920300126T patent/GR920300126T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2064112C (en) | 2002-12-31 |
| CA2064112A1 (en) | 1992-09-29 |
| ATE183093T1 (de) | 1999-08-15 |
| JPH04312590A (ja) | 1992-11-04 |
| EP0505608A3 (en) | 1993-02-03 |
| DE69131521D1 (de) | 1999-09-16 |
| DE505608T1 (de) | 1993-03-18 |
| DE69131521T2 (de) | 2000-03-30 |
| ES2052467T1 (es) | 1994-07-16 |
| EP0505608A2 (en) | 1992-09-30 |
| DK0505608T3 (da) | 2000-03-20 |
| ITMI910843A1 (it) | 1992-09-28 |
| ITMI910843A0 (it) | 1991-03-28 |
| KR100196445B1 (ko) | 1999-06-15 |
| IT1245369B (it) | 1994-09-20 |
| EP0505608B1 (en) | 1999-08-11 |
| GR920300126T1 (ko) | 1993-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
| KR920702216A (ko) | 아세틸 d-카르니틴의 녹내장 치료에의 용도 | |
| ES2160577T3 (es) | Nuevos esteres de aminoalcoholes biciclicos y triciclicos, su preparacion y su utilizacion en medicamentos. | |
| CA2093806A1 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
| KR950007841A (ko) | 트라마돌 염을 함유하는 서방성 약물 제제 | |
| HU892559D0 (en) | Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient | |
| CA2085344A1 (en) | Injectable Pharmaceutical Composition | |
| KR880002515A (ko) | 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물 | |
| KR940018089A (ko) | 내부조직의 방사선 손상에 대한 예방 및 처치방법 | |
| BR9401199A (pt) | Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento. | |
| KR900004326A (ko) | 디히드로에르고톡신 및 그의 산 부가염의 분산성 정제 | |
| MC2025A1 (fr) | Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee | |
| KR860006265A (ko) | 9,10-디하이드로 에르고트 알카로이드를 함유하는 서방성 제재의 제조방법 | |
| KR890007740A (ko) | 제약학적 조성물 | |
| KR920017652A (ko) | 신경보호활성을 갖는 α-디하이드로 에르고크립틴 약제학적 제제 | |
| KR900011461A (ko) | 트립스타틴을 유효성분으로 하는 치료제 | |
| KR890014109A (ko) | 의약제 | |
| ATE212550T1 (de) | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung | |
| UA66925C2 (uk) | Поліморфні форми кристалічного цитрату азабіцикло[2.2.2]-октан-3-аміну, спосіб їх одержання, фармацевтична композиція та спосіб лікування блювання | |
| JPS6416721A (en) | Antioxidant | |
| DE69803772D1 (de) | Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung | |
| DK0483320T3 (da) | Farmaceutiske sammensætninger med forlænget frigivelse til peroral indgivelse og fremgangsmåde til fremstilling deraf | |
| KR910004181A (ko) | 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태 | |
| KR920016104A (ko) | 노인성 특발적 백내장 약제 제조를 위한 칼시토닌의 국소적용 용도 및 이의 약제학적 조성물 | |
| Morril et al. | Haloperidol, chlorpromazine and apomorphine alter central regional neuropeptidase activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120217 Year of fee payment: 14 |
|
| EXPY | Expiration of term |